statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX - Free Report) from a neutral rating to a buy rating in a report published on Tuesday, Marketbeat.com reports. The firm...

Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Upgraded by LADENBURG THALM/SH SH

Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...

Evaxion Biotech Announces Upcoming Annual Meeting

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...

Evaxion Announces Business Update and Full Year 2023 Financial Results

The proprietary AI-Immunology platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology outcompetes...

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology  Platform

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion Biotech A/S (NASDAQ:EVAX  Free Report)  Equities researchers at HC Wainwright issued their FY2023 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued...

Evaxion Biotech A/S Expected to Post FY2023 Earnings of ($6.90) Per Share (NASDAQ:EVAX)

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Watchers	2,840
52-Wk Low	$2.82
52-Wk High	$18.50

Volume	566.00
52-Wk High	$18.50
52-Wk Low	$2.82

EVAX Evaxion Biotech

About

Feed

News

Fundamentals